Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Lessened by Park Avenue Securities LLC

Park Avenue Securities LLC reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,036 shares of the medical equipment provider’s stock after selling 753 shares during the quarter. Park Avenue Securities LLC’s holdings in Intuitive Surgical were worth $7,134,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Provence Wealth Management Group bought a new position in Intuitive Surgical during the fourth quarter valued at about $276,000. Sequoia Financial Advisors LLC boosted its holdings in Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after buying an additional 3,054 shares in the last quarter. Public Employees Retirement System of Ohio grew its position in Intuitive Surgical by 5.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after buying an additional 9,869 shares during the last quarter. HCR Wealth Advisors increased its holdings in shares of Intuitive Surgical by 26.3% in the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock valued at $352,000 after buying an additional 217 shares in the last quarter. Finally, Kades & Cheifetz LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at $230,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $385.55, for a total transaction of $92,146.45. Following the transaction, the executive vice president now owns 5,507 shares in the company, valued at $2,123,223.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares in the company, valued at $5,441,507.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 239 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $385.55, for a total value of $92,146.45. Following the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,123,223.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,005 shares of company stock worth $6,894,422. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Price Performance

ISRG traded up $1.60 during midday trading on Wednesday, hitting $449.26. 1,713,046 shares of the company’s stock traded hands, compared to its average volume of 1,574,429. The company has a market cap of $159.35 billion, a PE ratio of 82.85, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39. The stock’s fifty day simple moving average is $433.72 and its 200-day simple moving average is $402.67. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $468.78.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.18 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ISRG shares. Jefferies Financial Group lifted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Evercore ISI cut their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Barclays raised their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $442.30.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.